蛋白质组学对于阿尔茨海默症诊断标记物筛选的研究进展

发布时间：2018-06-16 15:32

本文选题：阿尔茨海默症 + 诊断标记物　；参考：《基因组学与应用生物学》2016年05期

【摘要】：阿尔茨海默症,简称AD(Alzheimer's Disease),是一类神经退行性疾病,主要发作于65岁以上老年人群中,患者会出现认知障碍、记忆缺失、言语障碍、抑郁、焦躁等症状,逐渐失去生活自理能力,目前已经成为严重的社会卫生问题。疾病中晚期实施的药物干预与治疗难以逆转病情,效果甚微,由于病理机制不明以及缺乏早期诊断标准,难以在疾病早期进行干预和治疗。好的生物标记物(biomarker)可在分子水平上为疾病提供敏感而稳定的诊断手段,蛋白质组学可高通量地识别样本中的蛋白质并对其含量进行分析,所以近些年来很多研究者们使用蛋白质组学手段进行了疾病诊断标记物的筛选。本文就利用蛋白质组学手段进行阿尔茨海默症诊断标记物筛选的研究进展做一论述。
[Abstract]:Alzheimer's disease is a kind of neurodegenerative disease, which occurs mainly in the elderly over 65 years old. The patients suffer from cognitive impairment, memory loss, speech disorder, depression, anxiety and so on, and gradually lose their ability to take care of themselves. At present, it has become a serious social health problem. The drug intervention and treatment in the middle and late stage of the disease is difficult to reverse the disease and has little effect. It is difficult to intervene and treat the disease in the early stage because of the unclear pathological mechanism and the lack of early diagnostic criteria. Biomarker, a good biomarker, provides a sensitive and stable diagnostic tool for disease at the molecular level, and proteomics allows high-throughput identification and analysis of proteins in samples. So in recent years, many researchers have used proteomics to screen disease diagnosis markers. This paper reviews the progress in screening diagnostic markers for Alzheimer's disease by proteomics.
【作者单位】：浙江大学医学院神经科学研究所卫生部医学神经生物学重点实验室脑科学协同创新中心;
【基金】：国家自然科学基金面上项目(31571049) 国家重点基础研究发展计划项目(2013CB530904)共同资助
【分类号】：R749.16

【相似文献】